Literature DB >> 16298519

Dyspnoea with activities of daily living versus peak dyspnoea during exercise in male patients with COPD.

Toru Oga1, Koichi Nishimura, Mitsuhiro Tsukino, Takashi Hajiro, Michiaki Mishima.   

Abstract

Dyspnoea measurements in chronic obstructive pulmonary disease (COPD) can be broadly divided into two categories: those that assess breathlessness during exercise, and those that assess breathlessness during daily activities. We investigated the relationships between dyspnoea at the end of exercise and during daily activities with clinical measurements and mortality in COPD patients. We examined 143 male outpatients with moderate to very severe COPD. The peak Borg score at the end of progressive cycle ergometry was used for the assessment of peak dyspnoea rating during exercise, and the Baseline Dyspnea Index (BDI) score was used for dyspnoea with activities of daily living. Relationships between these dyspnoea ratings with other clinical measurements of pulmonary function, exercise indices, health status and psychological status were then investigated. In addition, their relationship with the 5-year mortality of COPD patients was also analyzed to examine their predictive ability. Although the BDI score was significantly correlated with airflow limitation, diffusing capacity, exercise indices, health status and psychological status, the Borg score at the end of exercise had non-existent or only weak correlations with them. The BDI score was strongly significantly correlated with mortality, whereas the Borg score was not. Dyspnoea during daily activities was more significantly correlated with objective and subjective measurements of COPD than dyspnoea at the end of exercise. In addition, the former was more predictive of mortality. Dyspnoea with activities of daily living is considered to be a better measurement for evaluating the disease severity of COPD than peak dyspnoea during exercise.

Entities:  

Mesh:

Year:  2005        PMID: 16298519     DOI: 10.1016/j.rmed.2005.10.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  7 in total

1.  Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities.

Authors:  Donald A Mahler; Dorothy L Keininger; Karen Mezzi; Robert Fogel; Donal Banerji
Journal:  Chronic Obstr Pulm Dis       Date:  2016-09-09

2.  Measurement of dyspnea in patients with obstructive sleep apnea.

Authors:  Kensaku Aihara; Toru Oga; Chikara Yoshimura; Takefumi Hitomi; Yuichi Chihara; Yuka Harada; Kimihiko Murase; Yoshiro Toyama; Kiminobu Tanizawa; Tomohiro Handa; Tomomasa Tsuboi; Michiaki Mishima; Kazuo Chin
Journal:  Sleep Breath       Date:  2012-08-03       Impact factor: 2.816

3.  Airflow limitation or static hyperinflation: which is more closely related to dyspnea with activities of daily living in patients with COPD?

Authors:  Koichi Nishimura; Maya Yasui; Takashi Nishimura; Toru Oga
Journal:  Respir Res       Date:  2011-10-11

4.  Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease.

Authors:  Toru Oga; Mitsuhiro Tsukino; Takashi Hajiro; Akihiko Ikeda; Koichi Nishimura
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-10-11

5.  Analysis of longitudinal changes in dyspnea of patients with chronic obstructive pulmonary disease: an observational study.

Authors:  Toru Oga; Mitsuhiro Tsukino; Takashi Hajiro; Akihiko Ikeda; Koichi Nishimura
Journal:  Respir Res       Date:  2012-09-25

6.  Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease.

Authors:  Juan P de Torres; Ciro Casanova; Angela Montejo de Garcini; Armando Aguirre-Jaime; Bartolome R Celli
Journal:  Respir Res       Date:  2007-03-06

7.  Evaluation of quality of life with the chronic obstructive pulmonary disease assessment test in chronic obstructive pulmonary disease and the effect of dyspnea on disease-specific quality of life in these patients.

Authors:  Oguzhan Okutan; Dilaver Tas; Ersin Demirer; Zafer Kartaloglu
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.